

[Search the NLR Database](#)

[Latest Legal News](#)

[Events](#)

[Business of Law](#)

[Our Blog](#)

[About Us](#)

- [National](#)
- [Federal & Regulatory](#)
- [State](#)



CLICK HERE TO DOWNLOAD THE ULTIMATE BUSINESS PLAN TEMPLATE

Advertisement

February 28, 2014

Login



[International & Immigration](#)

SEARCH THE NATIONAL LAW REVIEW DATABASE

Quick Sign Up For NLR Bulletins: Articles drafted by experienced attorneys and other professionals. The National Law Review's [Advanced Search](#) you easily locate legal analysis in specific legal specialties or jurisdictions.

Search the NLR Database

[Advanced Search](#)



WHAT'S TRENDING:

[Internal Revenue Service \(IRS\) Issues New Foreign Account Tax Compliance Act of 2009 \(FATCA\) Regulations](#) from Katten Muchin Rosenman LLP



Advertisement

Food and Drug Administration (FDA) to Significantly Overhaul Inspection Operations

Article By:

[Seth A. Mailhot](#) (/author/seth-mailhot-1)

[Leah Hurtgen Ziemba](#) (/author/leah-hurtgen-ziemba)

(/author/seth-mailhot-1) [Michael Best & Friedrich LLP](#) (/organization/michael-best-friedrich-llp)

posted on: Wednesday, February 5, 2014

Administrative & Regulatory / Health Law & Managed Care
All Federal

[Printer-friendly](#)

<http://www.natlawreview.com/print/article/food-and-drug-administration-fda-to-significantly-overhaul-inspection-operations>

[Email this Article](#)

<http://www.natlawreview.com/printmail/article/food-and-drug-administration-fda-to-significantly-overhaul-inspection-operations>

[Download PDF](#)

<http://www.natlawreview.com/printpdf/27107>

[Reprints & Permissions](#) (/reprints-and-permissions)

Like 2 people like this. Be the first of your friends.



<http://www.michaelbest.com>

The **U.S. Food and Drug Administration (FDA)** released an internal memorandum to trade press this morning announcing a dramatic reorganization of FDA's inspection and compliance activities. The memorandum sent from Commissioner Margaret A. Hamburg on February 3, 2014, provides her decisions on recommendations made by the Program Alignment Group. The Program Alignment Group was tasked with identifying and developing plans to modify FDA's functions and processes in order to best achieve the Agency's mission-critical objectives.

The recommendations identified in the memorandum, when implemented, will drastically change FDA's inspection and compliance processes. In particular, the plan will change the current region-based inspection and compliance system to a product-based system. FDA also plans to 'de-layer' its management and review levels to shorten review time and enhance accountability.

Commissioner Hamburg identified eight decisions that will significantly change FDA's inspection and compliance activities:

Commodity-Based and Vertically-Integrated Regulatory Programs

FDA's enforcement operations are currently organized by geographical region, with district offices overseeing regulated industry within their identified areas. Operations within each district generally vary. While some districts task investigators with a specific commodity-type, other investigators, for logistical reasons, are designated as generalists covering multiple commodities. Generalists are more likely to be found in resident posts where regulated industry is less concentrated geographically. Some districts may even designate investigators with a secondary commodity specialty to provide flexibility in meeting workplans. While investigators tend to specialize in a specific commodity, compliance officers are more often generalists. They tend to be differentiated only by whether they handle import or domestic operations.

The change directed by Commissioner Hamburg will move FDA towards organizing its regulatory and compliance activities by commodity-type, with the following identified programs:

1. Pharmaceutical quality includes drugs and biologics regulated by Center for Drug Evaluation and Research (CDER) and veterinary drugs
2. Food and feeds
3. Medical devices and radiological health
4. Products regulated by Center for Biologics Evaluation and Research (CBER)
5. Tobacco
6. Bioresearch Monitoring (BIMO)

This will likely increase oversight that each Center has over inspection and compliance personnel. These employees are mostly part of the Office of Regulatory Affairs (ORA), which directly manages the district operations. This is viewed by FDA as allowing it to "speak" with one voice on policies and operations related to any given commodity."

Specialization

Employees in inspection and compliance roles will specialize in particular commodities. This will include compliance officers, who traditionally are more likely to be generalists. FDA also raises the possibility that some in the medical device commodity may even subspecialize due to the diversity in the industry.

Employees will be centrally managed in ORA commodity-specific offices that coordinate closely with the Center that oversees the specific commodity. The only exception to the Center oversight will be in the Bioresearch Monitoring (BIMO) program, which will be a shared responsibility of the relevant Centers, ORA and the Agency Office of Good Clinical Practice.

Training

In order to further the specialization of its inspectorate and compliance staff, FDA will revise its training program to develop a commodity-based set of competency requirements, training curricula, certification/qualification/accreditation processes, performance assessments, and a continuing education program. The training program should further the goal of providing regulated industry with a uniform, consistent application of regulatory standards.

Agency Work Planning

FDA plans to build a new program-based work planning system based on risk factors, public health outcomes, past inspectional history, and operational experience. The work planning system will incorporate a multi-year outlook on future priorities and activities in order to appropriately manage resources to meet future program needs.

Compliance Policy and Enforcement Strategy

FDA also plans to revise its compliance policies and enforcement strategies to limit the multiple layers of case review, inadequate coordination, and lack of prioritization, and will

designate firm lead roles in each commodity area to diminish the fragmentation of authority currently experienced by the Agency. FDA will also be developing what it calls "performance-based metrics" for compliance casework and other actions.

Imports

FDA will also apply a commodity-based approach to its import operations. This does not appear to be as sweeping as the proposed changes to domestic operations, but will include establishing import strategies by commodity, and focusing import operations consistent with Center designated, risk-based compliance strategies and policies.

Laboratory Optimization

FDA laboratories will also become more specialized and management will become more centralized. Laboratories under ORA, which are currently managed under the same geographic scheme as investigations and compliance operations, will ultimately report centrally to a senior executive level scientist leading the Office of Regulatory Science within ORA.

De-layering

FDA also intends to de-layer the management and review levels involved with enforcement actions. This would be implemented through the formation of specialized units in ORA operating program-based staffs directed and managed by commodity-specific offices and led by a senior executive.

Although these changes will not have an immediate direct impact on regulated industry, they will result in significant changes to FDA's inspections and compliance operations, potentially starting as early as the next fiscal year. Over time, this will result in a marked change to inspections and enforcement actions. As more details on these changes emerge, regulated industry may want to consider reviewing their procedures and policies related to FDA inspections.

© MICHAEL BEST & FRIEDRICH LLP

About The Author

[Seth A. Mailhot \(/author/seth-mailhot-1\)](#)

Member

Seth Mailhot leads the FDA Regulatory practice, and is a member of the firm's Transactional Practice Group in the Washington, D.C. office. Mr. Mailhot has worked on FDA-related matters for over 20 years, starting in various technical and enforcement positions at the U.S. Food and Drug Administration. Since entering private practice, Mr. Mailhot counsels clients on all aspects of regulation by FDA, as well as related matters regulated by USDA and Department of Health and Human Services (such as the requirements of the National Organic Program, and compliance with the Health...

samailhot@michaelbest.com (/NLR-email-disclaimer?email=samailhot@michaelbest.com)

202-747-9566

www.michaelbest.com (<http://www.michaelbest.com>)



[Leah Hurtgen](#)

[Ziemba \(/author/leah-](#)

[hurtgen-ziemba\)](#)

Associate

Leah Hurtgen Ziemba is an associate in the

Madison office of Michael Best and a member of the Energy and Sustainability Industry Group and Agribusiness, Food Processing and Distribution Group.

lhziemba@michaelbest.com (/NLR-email-disclaimer?email=lhziemba@michaelbest.com)

608-283-4420

www.MichaelBest.com (<http://www.MichaelBest.com>)



<http://www.natlawreview.com/ad/redirect/14781/t140?url=node/27107>

Legal Disclaimer

You are responsible for reading, understanding and agreeing to the National Law Review's (NLR's) and the National Law Forum LLC's [Terms of Use](#) and [Privacy Policy](#) before using the National Law Review website. The National Law Review is a free to use, no-log in [database](#) of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.

Some states have laws and ethical rules regarding solicitation and advertisement practices by attorneys and/or other professionals. The National Law Review is not a law firm nor is www.NatLawReview.com intended to be a referral service for attorneys and/or other professionals. The NLR does not wish, nor does it intend, to solicit the business of anyone or to refer anyone to an attorney or other professional. NLR does not answer legal questions nor will we refer you to an attorney or other professional if you request such information from us.

Under certain state laws the following statements may be required on this website and we have included them in order to be in full compliance with these rules. The choice of a lawyer or other professional is an important decision and should not be based solely upon advertisements. Attorney Advertising Notice: Prior results do not guarantee a similar outcome. Statement in compliance with Texas Rules of Professional Conduct. Unless otherwise noted, attorneys are not certified by the Texas Board of Legal Specialization, nor can NLR attest to the accuracy of any notation of Legal Specialization or other Professional Credentials.

The National Law Review - National Law Forum LLC 4700 Gilbert Ave. Suite 47 #230 Western Springs, IL 60558 Telephone (708) 357-3317 If you would like to contact us via email please [click here](#).